Collateral Consequences of White Collar Crime?

WSJ Law Blog spots a new development of interest to white collar criminal defense lawyers -- use of an obscure Social Security Act administrative policy that allows federal officials to bar corporate leaders of health-industry companies found guilty of criminal misconduct from doing business with the government. The case highlighted in this WSJ story (subs. req'd) is a ban against the CEO of Forest Labs, maker of Celexa and Lexapro, which agreed to pay $313M in criminal and civil penalties last fall over sales-related misconduct.  The CEO, Howard Solomon, was not accused of any misconduct. According to the story, lawyers not involved in the case said the attempt to punish an executive who wasn’t accused of misconduct "could tie up the industry’s day-to-day work in legal knots."